Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer (Cabo App)

Duke University logo

Duke University

Status

Terminated

Conditions

Metastatic Renal Cell Carcinoma Treated With Cabozantinib

Treatments

Device: Usability of an electronic symptom management application

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT03867045
Pro00086667

Details and patient eligibility

About

The purpose of this study is to develop an on-line electronic symptom management application that can ultimately be used to improve clinical outcomes in patients with mRCC treated with cabozantinib.

Full description

This is a single-site, prospective technology-based, clinical trial. Nine patients with mRCC initiating cabozantinib therapy who meet subject eligibility criteria will be enrolled in this study. Subjects will be given an iPOD touch with the symptom monitoring application installed, physical activity and blood pressure monitors. Each patient will be kept on study for the first 12 weeks of therapy with cabozantinib. Subjects on treatment for less than 12 weeks will not be replaced.The symptoms and other data (physical activity, blood pressure) recorded electronically by the patient will be compared to symptoms recorded in the medical record at interval clinic visits.

Enrollment

1 patient

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients > 18 years of age Patients planning to start treatment with cabozantinib therapy for renal cancer.

Technology requirement: The patient will need to have home wireless internet access for use of the software and technology in this study. The patient will need to already have or be willing to set up a Duke MyChart account.

Exclusion criteria

Non-English Speaking. Any patient who is not able to comprehend and operate the technology at the discretion of the enrolling provider.

Trial design

Primary purpose

Device Feasibility

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

1 participants in 1 patient group

mRCC treated with cabozantinib
Experimental group
Description:
Nine patients with mRCC initiating cabozantinib therapy who meet subject eligibility criteria.
Treatment:
Device: Usability of an electronic symptom management application

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems